BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Duoning Headquarters in Fengxian Biotechnology Park with Centers for R&D and Technology Applications

The global headquarters, R&D center, and TAC are located in the heart of the Biotechnology Park, with a total planned area of 20,029.8 m2. It...

January 31, 2023 | News

Junshi Biosciences Announces Approval for Marketing of VV116 in China

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...

January 31, 2023 | News

Alpha Biopharma Submits New Drug Application for Zorifertinib

Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA...

January 30, 2023 | News

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic ma...

January 23, 2023 | News

Zhongchao Inc. Launches Medication Management Assistance Mini Program to Facilitate Cancer Treatment

Zhongxin launched the Program aiming to navigate and solve the medication challenges faced by cancer patients. During cancer treatment process, the use of ...

January 20, 2023 | News

Strength in sustainability: Vetter wins gold in EcoVadis ranking

Vetter among the top five percent in the industry Result acknowledges strong sustainability commitment to the environment, social sector and...

January 18, 2023 | News

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

World's first anti-PD-1 mAb for the first-line treatment of SCLC Making a new record with the median OS of 15.8 months in an international, mult...

January 18, 2023 | News

China NMPA Approves Bio-Thera Solutions’ BAT1806, A Biosimilar to Actemra® (Tocilizumab)

Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, announced that the China National Medical Products Administration (NM...

January 18, 2023 | News

FAPON presents at 41st Annual J.P. Morgan Healthcare Conference

FAPON focuses on three business lines: raw materials and solutions, the IVD ecosystem, and intelligent digital diagnosis & treatment. Supported by its ...

January 17, 2023 | News

AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to address critical unmet medical needs in neurological, psyc...

January 17, 2023 | News

Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere

Ritonavir tablet is a pharmacokinetic booster of multiple oral antiviral protease inhibitors. Ascletis currently owns the only authorized ritonavir oral ta...

January 17, 2023 | News

MGI Demonstrates Strong Commitment to Expanding Genomic Access in Europe

With a commitment to building core tools and technology to lead life science, MGI Tech Co., Ltd. (or its affiliates, referred to as "MGI") is dedicated to ...

January 16, 2023 | News

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

This double-blind, randomized, placebo-controlled, multicentre Phase 2b study will evaluate the effect of HTD1801, 1250 mg twice daily (BID), compared to p...

January 11, 2023 | News

Bio4t2 announces first patient infused with CAR-T targeting solid tumors

"This first-in-human study marks the initial therapeutic to be evaluated from Bio4t2's technology," said Dr. Laurence Cooper MD-PhD, Executive Ch...

January 11, 2023 | News

Stay Connected